The endothelium produces and responds to reactive oxygen and nitrogen species (RONS), providing important redox regulation to the cardiovascular system in physiology and disease. In no other situation are RONS more critical than in the response to tissue ischemia.
Introduction
Reactive oxygen, eg. superoxide anion and hydrogen peroxide, and reactive nitrogen species, eg. nitric oxide and peroxynitrite, (RONS) are low molecular weight reactive species created as a result of metabolism in respiring cells. Elevated levels of RONS have been measured in countless studies of various cardiovascular and metabolic diseases, notably diabetes mellitus, and in animal models, scavenging of the oxidants has therapeutic benefits.
When they are present at high levels or for prolonged times, one of the most prevalent reasons for the adverse effects of RONS is the irreversible damage to proteins, requiring protein degradation and re-synthesis to return protein function. Such damage is evidenced by biologically irreversible post-translational chemical modifications. Although many such modifications have been identified, the one with most notoriety is nitrotyrosine 1 due to the early development of a specific antibody. Nitrotyrosine, and other irreversible oxidative posttranslational modifications (OPTM), chlorotyrosine, methionine sulfoxide, and cysteine sulfonic acid (-SO 3 H), are all recognized biomarkers of oxidant stress occurring in animal models and found in tissue and blood of human patients with cardiovascular disease 2, 3, 4, 5, 6 . These biomarkers have been demonstrated on proteins whose functions are essential to cellular homeostasis, including albumin 7 , endothelial nitric oxide synthase (eNOS) 8 , prostacyclin synthase 9 , the sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA) 10, 11 , manganese superoxide dismutase 12 , and p21Ras 13 . As an example, nitrotyrosine-modified proteins accumulate in endothelial cells of skeletal muscle in a commonly used mouse model of hindlimb ischemia 14, 15 . In this model, a one centimeter length of the femoral artery is ligated and excised, allowing serial measurements of blood flow and other parameters over several weeks, during which angiogenesis and revascularization return blood flow to near normal. As another example of irreversible protein oxidation within endothelial cells during hindlimb ischemia in the mouse, the reactive cysteine-674 thiol of SERCA2 is in part irreversibly oxidized to the sulfonic acid as revealed by a specific antibody (Figure 1 ).
Signaling in endothelial cells by thiol adducts
Lower levels of RONS are now recognized to be essential for cell signaling functions.
For example, there is substantial evidence that nitric oxide (NO) is an endogenous mediator of growth factor-mediated angiogenesis 16 , and in therapeutic amounts, NO can provide substantial protection from the effects of ischemia 17 . Also, interference with normal functions of low-level RONS is a potential reason why application of non-specific scavenging antioxidants such as vitamin C and E have failed as therapies for diseases involving damage caused by high levels of RONS. These factors suggest that mammalian cells have developed mechanisms to utilize low levels of RONS, while protecting themselves from higher levels.
While not exclusively so, the major signaling actions of RONS are mediated by reversible protein modifications on cysteine residues 18, 19, 20 . Alterations in function are associated with multiple oxidative modifications of the thiol group ( Figure 2) . The primary targets include cysteines that are accessible on the protein surface, as well as those that are maintained in the chemically reactive thiolate anion state (-S -rather than -SH) by nearby positively charged arginine and lysine amino acids. Although high concentrations of RONS widely oxidize cysteines and other amino acids on proteins, low levels of RONS affect these reactive cysteines more specifically. As an example, during growth factor initiated signaling in endothelial cells, the thiol of cysteine-674 of SERCA2 serves as the exclusive target for glutathione (GSH) adducts. Despite the fact that there are many other cysteine thiols on the exterior of the protein, a cysteine to serine mutation of this one thiol nearly eliminates all GSH adducts occurring on the protein during growth factor-induced angiogenesis 21 . NO is well documented to produce S-nitroso thiols (-SNO), and hydrogen peroxide to produce sulfenic acid (-SOH) modification of thiols 22, 23 . However, both of these thiol modifications readily react with abundant intracellular GSH to form the more stable GSH adduct (-SSG). In response to direct challenge with various oxidants in vitro, or in particular in response to ischemia in vivo, large amounts of glutathione adducts appear on reactive cysteines. As an example, during the first 24 hours of ischemia, cysteine-674 of SERCA2 abundantly forms GSH adducts that persist for at least several days ( Figure 3 ).
Glutaredoxin-1
Likely because of the chemical stability of GSH cysteine adducts, the cell has evolved several thiol reductase enzymes that can remove GSH adducts. While thioredoxins and peroxidoxins are abundant thiol reductases, glutaredoxin-1 (Glrx1) is the most selective in its ability to remove GSH protein adducts 3 . This 12 kiloDalton protein removes GSH adducts from a protein cysteine thiol by transferring the GSH adduct to one of its own reactive thiols on cysteine 23 or 26. Glrx1 is then reduced by free GSH, completing the catalytic cycle ( Figure 4 ).
There is growing awareness of the importance of Glrx1 as a physiological regulator [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Our studies show that Glrx1 regulates hindlimb ischemia, when the abundance of GSH adducts is high. The level of protein GSH adducts present in ischemic muscle and the restoration of blood flow during the two weeks following femoral artery excision was significantly enhanced in global Grx1 knockout mice 35 , consistent with an essential role of GSH adducts in the response to ischemia. In contrast, GSH adducts in the ischemic muscle were decreased and restoration of blood flow was impaired in global Glrx1 overexpressing transgenic mice ( Figure 5 ) 28 .
Additionally, when compared to wild type mice, endothelial-specific overexpression of Glrx1 impaired the recovery from ischemia, resulting in necrotic loss of toes 35 ., Together, these findings indicate a critical role for GSH adducts on endothelial cell proteins during the response to ischemia. Furthermore, these studies establish Grx1 as a critical regulator and potential therapeutic target to address in improving clinical outcomes of limb ischemia.
Redox regulation of cellular mechanisms of angiogenesis in endothelial cells
During a normal response to ischemia induced by femoral artery excision, the involvement of RONS is well established. Throughout the subsequent recovery of blood flow, collateral arteries grow in diameter to conduct blood flow around the blocked artery, and the numbers of capillaries increase within ischemic muscle tissue. The increase in number of capillaries, termed angiogenesis, requires endothelial cell proliferation and migration driven by increased production by the ischemic cells of growth factors, the most abundant of which is vascular endothelium growth factor (VEGF). superoxide anion from Nox2 appear to be required for NO to perform its angiogenic functions.
The requirements for nitric oxide, Nox4-derived H 2 O 2 , and Nox2-derived superoxide anion to achieve a normal angiogenic response to VEGF also extend to the ability of the growth factor to stimulate protein GSH adducts in endothelial cells in culture 36 . This is also compatible with the previously noted suggestion that ONOO -is essential for protein GSH adducts to form in sufficient abundance for VEGF signaling. Indeed, like the scavengers of RONS mentioned above, overexpression of Glrx1 prevents formation of GSH protein adducts and completely prevents VEGF-induced angiogenic responses in cultured endothelial cells 21 .
Involvement of GSH adducts on specific proteins in the redox regulation of angiogenesis

It is clear from proteomics studies of endothelial cell proteins on which GSH adducts
form during ischemia, that multiple, perhaps hundreds of, proteins are involved 35, 43 . This is as might be expected, given that ischemia results in high concentrations of RONS and hundreds of proteins have been identified to have reactive cysteines 44 . While it is uncertain if and how all the proteins on which GSH adducts occur are involved in the angiogenic response, it is certain that several are essential.
GSH adducts on the cysteine-674 thiol of SERCA2 are one example of a mechanistically essential GSH adduct. First, GSH adducts form abundantly on the SERCA2 thiol during the first 3 days of ischemia (Figure 3 ). The importance of this cysteine was demonstrated in a heterozygote mouse in which one allele of SERCA2 was mutated to encode a serine in place of cysteine-674 45 . Total GSH adducts on SERCA2 in ischemic muscle were decreased approximately 50%, consistent with this single thiol being the primary site for GSH adduct formation on SERCA2 21, 39 . In cultured endothelial cells, knockdown of SERCA2 expression prevented VEGF-induced calcium influx, cell migration, and capillary-like network formation. The importance of SERCA2 was attributed to its role in refilling intracellular calcium stores, which, in turn, regulates entry of the extracellular calcium required for angiogenic responses to VEGF. Overexpression of a SERCA2 cysteine-674 serine mutant or overexpression of Glrx1 in endothelial cells largely prevented increases in GSH adducts on SERCA2, calcium signaling, and angiogenic responses to VEGF. In addition, the mouse in which 50% of the redox-sensitive cysteines were mutated to serine showed impaired restoration of blood flow in the ischemic hindlimb (Figure 3) . The fundamental importance of GSH adducts on cysteine-674 of SERCA2 for growth factor-mediated angiogenesis was also evidenced by the fact that the mouse with homozygote substitution of the SERCA2 serine mutation died in utero at the stage when heart and vascular development occur 45 .
GSH protein adducts on any of several components involved in NFkB signaling inhibits activation of the pathway, i.e. by inactivating IKK 25 and limiting the DNA binding ability of p65 46 and p50 47 . For example, increased GSH adducts were noted on p65 in normal ischemic hindlimb muscle and endothelial cells exposed to hypoxia, suggesting that during ischemia, NFkB activity is inhibited by glutathione adduct formation ( Figure 5 ). On the contrary, NFkB activity is dramatically increased in endothelial cells cultured from transgenic mice overexpressing Glrx1 28 . Overexpression of Glrx1 in endothelial cells prevented p65 GSH adducts and resulted in the activation of NFkB. A consequence of this activation was increased production of the non-canonical Wnt ligand, Wnt5a, levels of which rose dramatically in the ischemic hindlimbs of Glrx1 transgenic mice. Wnt5a, in turn, increased production of soluble Flt, an alternatively spliced VEGF receptor that acts as a decoy, interfering with binding and response to VEGF 28 . Knocking down the expression of sFlt restored angiogenic function to endothelial cells that overexpressed Glrx1 28 . Regulation and downstream targets of NF-kB are, however, complex. However, mice with dominant negative IκBα, in which NF-kB is inhibited,
showed decreased blood flow recovery after hindlimb ischemia 48 . Induction of sFlt in Glrx1 overexpressing mice may result not only from NF-kB activation but also other transcriptional controls regulated by GSH adducts.
Phosphatases (eg. protein tyrosine phosphatase-1B and protein phosphatase-2A) are protein targets that are inhibited by oxidants, resulting in increased phosphorylation and activation of kinase signaling. VEGF was shown to induce increases in GSH adducts on low molecular weight protein tyrosine phosphatases 49 . In cultured endothelial cells, inhibition of the phosphatases by GSH adducts was required for increases in tyrosine phosphorylation and increased activity of focal adhesion kinase, a key mediator of endothelial cell migration. Either antioxidants or a ONOO -decomposition catalyst were able to prevent GSH adducts from forming on the phosphatase, and thus prevented kinase activation. These studies indicate that endothelial cell migration requires GSH adducts and inhibition of the phosphatase to allow downstream kinase signaling.
p21ras is essential for angiogenesis. Glutathione adducts on cysteine 118 of p21ras substantially increase its activity 50 , so it is possible that this small GTPase is another key protein that is redox-regulated by GSH adducts during ischemic angiogenesis. It is known that mutation of cysteine-118 in p21ras prevents a critical angiogenic role of eNOS in tumor maintenance 51 , making it likely that GSH adducts are involved.
Whereas GSH adducts on the above cited proteins would appear to aid in the restoration of blood flow during ischemia, GSH adducts on some proteins known to be essential in the angiogenic response to ischemia may have adverse consequences. For example, both eNOS 16 and sirtuin-1 52 are essential to normal angiogenesis and possess reactive cysteines that when adducted with GSH affect their function. However, GSH adducts on both eNOS 32 and sirtuin-1 53 inhibit their catalytic activities, which would therefore be predicted to have a deleterious effect on ischemia-induced angiogenesis. As GSH adducts on both proteins are reduced by Grx1 54,32 , the deleterious effect of Grx1 itself cannot be explained. This apparent contradiction could exist for several reasons, including the possibility that these proteins are protected from GSH adducts during ischemia because of subcellular localization (eg. calveoli and nucleus, respectively), or that the global effects of up-or downregulation of Grx1 expression overrides changes in the function of these two proteins. It is also possible that because GSH adducts on eNOS uncouple the enzyme 32 , the increased ONOOthat results may benefit VEGF signaling by further increasing GSH adducts.
Summary and future directions
It is now evident that GSH adducts form abundantly on proteins during ischemia, and that from studies of up-and down-regulation of Grx1, formation of these adducts is important to the outcome of ischemia. It is possible that the benefit of GSH adducts on many proteins during ischemia is derived from protecting critical reactive cysteines against potential irreversible oxidation.The resulting preservation of cysteine function could explain the adverse consequences of overexpression and the benefit of knockdown of Grx1. This then suggests that inhibition of Grx1, because of its generalized effects on GSH adducts during ischemia, might be one therapeutic maneuver identified by these studies. It is also possible to affect GSH adduct formation by influencing GSH levels and the redox state of GSH itself, which is regulated by GSH reductase and GSH synthase, amongst other factors.
The global increase in GSH adducts during ischemia is difficult to reconcile with the apparent importance of the redox state of reactive cysteines in the function of individual proteins. The evidence, for instance, that GSH adducts on one cysteine of SERCA are essential to angiogenic growth factor signaling and that a 50% substitution of the cysteine inhibits ischemic angiogenesis in vivo, suggests that GSH adducts on some proteins might be more important than on others. If this is so, it might be possible to use the redox state of these particular cysteines, such as was measured for SERCA cysteine-674 with immunohistochemistry in Figure 1 , as an indicator or biomarker of a favorable or unfavorable response to ischemia. Potentially, proteins have evolved with reactive cysteines, in part, for protection from ischemia, or other acute adverse redox conditions. This notion is supported by preliminary proteomic studies that we designed to identify which endothelial cell proteins have GSH adducts on reactive cysteines. Using systems biology approaches, these studies show that many proteins in several categories of tissue healing and angiogenesis have increased adducts during prolonged hypoxia, raising the possibility that protection of these categories of proteins in particular has evolved to improve the response to adverse oxidative stress conditions including ischemia. Future systems biology analysis might reveal that proteins with essential reactive cysteines work not alone, but in unison to accomplish a normal response to ischemia.
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